A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

2017

Background We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

34

References

42

Citations